ATE178616T1 - Verfahren zur herstellung von biologisch aktivem protein (z.b. tgf) - Google Patents

Verfahren zur herstellung von biologisch aktivem protein (z.b. tgf)

Info

Publication number
ATE178616T1
ATE178616T1 AT90810922T AT90810922T ATE178616T1 AT E178616 T1 ATE178616 T1 AT E178616T1 AT 90810922 T AT90810922 T AT 90810922T AT 90810922 T AT90810922 T AT 90810922T AT E178616 T1 ATE178616 T1 AT E178616T1
Authority
AT
Austria
Prior art keywords
tgf
biologically active
active protein
producing biologically
beta
Prior art date
Application number
AT90810922T
Other languages
English (en)
Inventor
Nico Dr Cerletti
Gary Kent Dr Mcmaster
David Dr Cox
Albert Dr Schmitz
Bernd Dr Meyhack
Original Assignee
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh
Application granted granted Critical
Publication of ATE178616T1 publication Critical patent/ATE178616T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT90810922T 1989-12-06 1990-11-27 Verfahren zur herstellung von biologisch aktivem protein (z.b. tgf) ATE178616T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898927546A GB8927546D0 (en) 1989-12-06 1989-12-06 Process for the production of biologically active tgf-beta

Publications (1)

Publication Number Publication Date
ATE178616T1 true ATE178616T1 (de) 1999-04-15

Family

ID=10667491

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90810922T ATE178616T1 (de) 1989-12-06 1990-11-27 Verfahren zur herstellung von biologisch aktivem protein (z.b. tgf)

Country Status (23)

Country Link
US (2) US5650494A (de)
EP (2) EP0433225B1 (de)
JP (1) JP3048061B2 (de)
KR (1) KR100203230B1 (de)
AT (1) ATE178616T1 (de)
AU (1) AU638075B2 (de)
CA (1) CA2031430C (de)
DE (1) DE69033040T2 (de)
DK (1) DK0433225T3 (de)
ES (1) ES2132066T3 (de)
FI (1) FI103278B (de)
GB (1) GB8927546D0 (de)
GR (1) GR3030703T3 (de)
HU (1) HU218144B (de)
IE (2) IE990992A1 (de)
IL (1) IL96549A (de)
MX (1) MX172600B (de)
NO (1) NO301768B1 (de)
NZ (1) NZ236333A (de)
PH (1) PH31649A (de)
PT (1) PT96068B (de)
SG (1) SG52690A1 (de)
ZA (1) ZA909762B (de)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
AU664021B2 (en) * 1990-09-05 1995-11-02 Natinco Nv Solubilization of proteins in active forms
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
WO1993009229A1 (en) 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US20080139474A1 (en) * 1991-11-04 2008-06-12 David Israel Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
AU2738392A (en) * 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US6884787B2 (en) * 2001-07-14 2005-04-26 Isis Pharmaceuticals, Inc. Antisense modulation of transforming growth factor-beta 3 expression
DE4243729A1 (de) * 1992-12-23 1994-06-30 Behringwerke Ag Verfahren zur Reaktivierung von gereinigten Membranproteinen
KR960700271A (ko) * 1993-01-08 1996-01-19 로렌스 티. 웰츠 인간 호흡계 합포체 바이러스 fg 당단백질의 정제 및 리폴딩 방법(process for the purification and refolding of human respiratory syncytial virus fg glycoprotein)
DE69432375T2 (de) 1993-04-30 2004-02-12 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense Oligonukleotide zur Behandlung von immunsuppressiven Wirkungen von TGF-beta2
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
AU7846894A (en) * 1993-09-29 1995-04-18 Alcon Laboratories, Inc. Compositions containing growth factors and antiplastic agents
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
EP0733109B9 (de) * 1993-12-07 2006-07-05 Genetics Institute, LLC Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US6027919A (en) 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
TW517059B (en) * 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
CA2194177A1 (en) * 1994-07-25 1996-02-08 Jui Yoa Chang Process for folding of proteins like recombinant hirudin or epidermal growth factor
TW440566B (en) * 1994-07-25 2001-06-16 Novartis Ag Novel process for the production of biologically active dimeric protein
PL186518B1 (pl) * 1995-04-19 2004-01-30 Bioph Biotech Entw Pharm Gmbh Białko, kompozycja farmaceutyczna i sposób wytwarzania białka
US5714371A (en) * 1995-05-12 1998-02-03 Schering Corporation Method for refolding insoluble aggregates of hepatitis C virus protease
US6352972B1 (en) * 1995-06-06 2002-03-05 Marcel E. Nimni Bone morphogenetic proteins and their use in bone growth
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
US6040431A (en) * 1995-06-07 2000-03-21 Stryker Corporation Single chain analogs of the TGF-β superfamily (morphons)
CA2235223A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
US6084076A (en) * 1995-12-21 2000-07-04 Ajinomoto Co., Inc. Method of refolding human activin A
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
DE69737809T2 (de) * 1996-01-22 2008-02-21 Curis, Inc., Cambridge Methoden zur herstellung von op-1 morphogen analoge
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US7811793B2 (en) 1996-12-25 2010-10-12 Biopharma Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Process for preparing purified active monomer of bone-derived factor
US6500920B1 (en) * 1997-06-19 2002-12-31 St. Louis University Inhibitor of transforming growth factor β and A method of inhibiting the biological effects of transforming growth factor
US7723473B2 (en) 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
DE69714035T2 (de) 1997-08-14 2003-03-06 Sulzer Innotec Ag Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren
US20020052026A1 (en) 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
DE19749259A1 (de) * 1997-11-07 1999-05-12 Dade Behring Marburg Gmbh Verfahren zur Herstellung von funktionalem rekombinantem Gewebsfaktor
DK1659179T3 (da) * 1998-02-05 2011-10-10 Glaxosmithkline Biolog Sa Tumor-associerede antigenderivater fra MAGE-familien og nucleinsyresekvenser kodende for dem anvendt til fremstilling af fusionsproteiner og sammensætninger til vaccination
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
CA2657302A1 (en) * 1998-10-07 2000-04-13 Hermann Oppermann Modified tgf-.beta. superfamily proteins
US6846906B1 (en) 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
US6677432B1 (en) 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
US7087577B2 (en) 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US6992066B2 (en) 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
EP1142908A4 (de) * 1999-01-07 2002-05-22 Takeda Chemical Industries Ltd Methode zum herstellen von aktivierten proteinen
US6727224B1 (en) * 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
DE19906096A1 (de) 1999-02-13 2000-08-17 Walter Sebald Protein mit einem Heparin-bindenden Epitop
CA2643162C (en) 1999-04-23 2018-01-02 Massachusetts Institute Of Technology Polymer identification, compositional analysis and sequencing, based on property comparison
DE19944626A1 (de) * 1999-09-17 2001-03-22 Knoell Hans Forschung Ev Verfahren zur Herstellung von dimeren, biologisch aktiven knochenmorphogenetischen Proteinen
AU4351201A (en) 2000-03-08 2001-09-17 Massachusetts Inst Technology Heparinase iii and uses thereof
DE10026713A1 (de) * 2000-05-30 2001-12-06 Walter Sebald Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
US7081240B1 (en) * 2000-06-28 2006-07-25 Zimmer Orthobiologics, Inc. Protein mixtures for wound healing
PT1319183E (pt) 2000-09-12 2009-06-29 Massachusetts Inst Technology Métodos e produtos relacionados a heparina de baixo peso molecular
US7709461B2 (en) 2000-10-18 2010-05-04 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
HUP0303246A2 (hu) 2001-02-23 2003-12-29 Immunex Corporation Aktív fehérjék fokozott kinyerése
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
WO2002099037A2 (en) * 2001-06-01 2002-12-12 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
ES2629395T3 (es) 2001-10-04 2017-08-09 Genetics Institute, Llc Métodos y composiciones para modular la actividad de la interleucina-21
US7232802B2 (en) 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
SI1472286T1 (sl) * 2002-02-05 2007-08-31 Geymonat Spa Postopek proizvodnje rekombinantnega placentnega rastnega faktorja
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
JP2006508049A (ja) * 2002-08-13 2006-03-09 ワイエス 増殖因子βタンパク質を形質転換するための可溶化賦形剤としてのペプチド
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
US7074412B2 (en) 2003-01-30 2006-07-11 The University Of Zurich Pharmaceutical composition
CA2864810A1 (en) 2003-04-18 2004-11-04 Biogen Idec Ma, Inc. Polymer-conjugated glycosylated neublastin
DE602004005477T2 (de) 2003-09-12 2007-12-13 Wyeth Injizierbare feste Calciumphosphat-Stäbe zur Abgabe von osteogenen Proteinen
EP2335650B1 (de) 2003-12-11 2012-10-03 Isto Technologies Inc. Teilchenförmiges Knorpelsystem
EP2238983B1 (de) * 2004-08-19 2014-07-23 Biogen Idec MA Inc. Neublastinvarianten
NZ553420A (en) 2004-08-19 2010-02-26 Biogen Idec Inc Refolding transforming growth factor beta family proteins
WO2006081379A1 (en) * 2005-01-26 2006-08-03 Wyeth Use of sfrps as markers of bmp activity
AU2006214384A1 (en) 2005-02-14 2006-08-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of IL-17F in diagnosis and therapy of airway inflammation
CN102178953A (zh) 2005-02-14 2011-09-14 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
US20060239951A1 (en) * 2005-03-30 2006-10-26 Alexandre Valentin Methods for stimulating hair growth by administering BMPs
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
GB0514262D0 (en) * 2005-07-12 2005-08-17 Renovo Ltd Promotion of epithelial regeneration
BRPI0613653A2 (pt) * 2005-07-25 2011-01-25 Trubion Pharmaceuticals Inc composições e métodos para desagregação de proteìna
GB0516204D0 (en) * 2005-08-06 2005-09-14 Riotech Pharmaceuticals Ltd Methods
US8480757B2 (en) 2005-08-26 2013-07-09 Zimmer, Inc. Implants and methods for repair, replacement and treatment of disease
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
ES2450065T3 (es) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
US7582609B2 (en) * 2006-03-01 2009-09-01 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
GB0604966D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Medicaments and proteins
GB0604964D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Protein folding
GB0604938D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
AR062069A1 (es) * 2006-07-14 2008-10-15 Genentech Inc Replegado de proteinas recombinantes
GB0617816D0 (en) * 2006-09-11 2006-10-18 Renovo Ltd Nucleic acids and methods of protein expression
PL2078071T3 (pl) 2006-11-08 2015-07-31 Wyeth Llc Racjonalnie opracowane pożywki do hodowli komórek
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
AU2008240191B2 (en) 2007-04-12 2013-09-19 Zimmer, Inc. Compositions and methods for tissue repair
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US8329655B2 (en) * 2007-05-01 2012-12-11 Biogen Idec Ma Inc. Methods for increasing vascularization
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
ES2657055T3 (es) 2007-08-09 2018-03-01 Wyeth Llc Uso de perfusión para mejorar la producción de un cultivo de células alimentado por lotes en biorreactores
US8946201B2 (en) 2007-08-27 2015-02-03 Saint Louis University Methods for inhibiting TGF-β
WO2010033507A1 (en) 2008-09-16 2010-03-25 St. Louis University Method of enhancing tgf-beta signalling
US8494140B2 (en) * 2008-10-30 2013-07-23 Centurylink Intellectual Property Llc System and method for voice activated provisioning of telecommunication services
ES2699434T3 (es) 2008-10-31 2019-02-11 Wyeth Llc Purificación de proteínas ácidas utilizando cromatografía de hidroxiapatita cerámica
BRPI1011940B8 (pt) * 2009-06-22 2021-08-03 Amgen Inc método de redobramento de uma proteína expressa em um sistema de expressão de não mamífero
EP2445924B2 (de) 2009-06-25 2023-12-13 Amgen Inc. Vefahren zur aufreinigung von proteinen aus prokaryotischen zellen
KR100991203B1 (ko) * 2010-05-10 2010-11-01 심영복 골형성 단백질의 정제 방법
US20140148387A1 (en) 2010-09-01 2014-05-29 Masahiro Nagaya Freeze-dried recombinant human bone morphogenetic protein-2 preparation
TWI649095B (zh) * 2012-02-10 2019-02-01 捷百克股份有限公司 以非人類幹細胞之培養上清液為起始材料之化妝品或皮膚再生促進劑、及蛋白質之離子導入法
WO2014025771A2 (en) * 2012-08-06 2014-02-13 Biogen Idec Ma Inc. Methods and compositions for inactivating enveloped viruses
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
CA3048735A1 (en) 2016-12-30 2018-07-05 Biogend Therapeutics Co., Ltd. Recombinant polypeptides, compositions, and methods thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811970B (en) * 1980-03-27 1982-11-24 Lilly Co Eli Process for producing an insulin
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
GR79124B (de) * 1982-12-22 1984-10-02 Genentech Inc
WO1984004924A1 (en) * 1983-06-03 1984-12-20 Us Commerce Purified transforming growth factor-beta derived from human platelets and placentas
DE3587022T2 (de) * 1984-02-17 1993-06-17 Genentech Inc Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4731440A (en) * 1985-02-22 1988-03-15 Monsanto Company Method of somatotropin solubilization using dimethylsulfone and naturation
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
GB8508340D0 (en) * 1985-03-29 1985-05-09 Creighton T E Production of protein
EP0208539A3 (de) * 1985-07-11 1988-08-03 Repligen Corporation In Falten gelegte Proteine, durch Disulfid gebunden
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
NZ222168A (en) * 1986-10-20 1991-05-28 Oncogene Science Inc Tumour growth inhibiting protein related to tgf-#b#1 and tgf-#b#2, preparation by genetic engineering methods, antibodies and pharmaceutical compositions
KR890700031A (ko) * 1986-11-17 1989-03-02 예안 크라메르 한스 루돌프 하우스 신규한 t-세포 억압 인자의 제조 및 그것의 용도
FI100106B (fi) * 1986-12-05 1997-09-30 Novartis Ag Menetelmä plasminogeenin yksisäikeisen yhdistelmäaktivaattorin valmist amiseksi
US4931548A (en) * 1987-01-30 1990-06-05 Techne Corporation Heterodimer form of transforming growth factor-beta
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US5162507A (en) * 1987-05-11 1992-11-10 Cetus Corporation Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
DE3855986T2 (de) * 1987-05-11 1998-02-05 Chiron Corp Prozess zur gewinnung von gereinigtem, oxidiertem, renaturiertem, rekombinantem interleukin-2 aus mikroorganismen
AU626524B2 (en) * 1987-05-29 1992-08-06 Bristol-Myers Squibb Company Cloning and expression of simian transforming growth factor- beta 1
US4985544A (en) * 1987-08-04 1991-01-15 Kyowa Hakko Kogyo Co., Ltd. Process for renaturing fish growth hormone
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5144006A (en) * 1991-06-13 1992-09-01 The Rockefeller University Oxidative folding of peptide and protein substrates using hydrocarbon sulfoxides
AU2738392A (en) * 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors

Also Published As

Publication number Publication date
JPH03191791A (ja) 1991-08-21
ES2132066T3 (es) 1999-08-16
US5922846A (en) 1999-07-13
EP0433225A1 (de) 1991-06-19
CA2031430C (en) 2003-05-27
FI905956A (fi) 1991-06-07
EP0433225B1 (de) 1999-04-07
HU218144B (hu) 2000-06-28
HUT56880A (en) 1991-10-28
AU6701890A (en) 1991-06-13
KR100203230B1 (ko) 1999-06-15
PT96068B (pt) 1998-02-27
DE69033040T2 (de) 1999-09-09
HU908084D0 (en) 1991-06-28
FI905956A0 (fi) 1990-12-03
AU638075B2 (en) 1993-06-17
NZ236333A (en) 1992-03-26
JP3048061B2 (ja) 2000-06-05
KR910012240A (ko) 1991-08-07
PT96068A (pt) 1991-09-30
IL96549A (en) 2000-10-31
ZA909762B (en) 1991-08-28
GB8927546D0 (en) 1990-02-07
DE69033040D1 (de) 1999-05-12
IE904386A1 (en) 1991-06-19
NO905264D0 (no) 1990-12-05
DK0433225T3 (da) 1999-10-25
FI103278B1 (fi) 1999-05-31
IE990992A1 (en) 2000-12-13
IL96549A0 (en) 1991-09-16
EP0891985A1 (de) 1999-01-20
MX172600B (es) 1994-01-03
GR3030703T3 (en) 1999-11-30
NO301768B1 (no) 1997-12-08
NO905264L (no) 1991-06-07
CA2031430A1 (en) 1991-06-07
FI103278B (fi) 1999-05-31
US5650494A (en) 1997-07-22
PH31649A (en) 1999-01-12
SG52690A1 (en) 1998-09-28

Similar Documents

Publication Publication Date Title
ATE178616T1 (de) Verfahren zur herstellung von biologisch aktivem protein (z.b. tgf)
DE3855921D1 (de) Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein
DE68928934T2 (de) Verfahren zur herstellung von menschlicher dnase
DE59003771D1 (de) Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte.
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
DE69224124T2 (de) Verfahren zur Herstellung von Dihomo-Gamma-Linolensäure und das in dieser enthaltende Lipid
ATE68826T1 (de) Verfahren zur herstellung von reifem, menschlichem serum-albumin.
DE69427955T2 (de) Verfahren zur Herstellung von 2,2-Difluorketensilylacetalen und alpha,alpha-Difluor-beta -Silyloxy-1,3-Dioxolan-4-Propansäureestern
DE68919282D1 (de) Verfahren zur Herstellung von Cephalosporin und Zwischenverbindungen.
ATA267788A (de) Verfahren zur herstellung von polynucleotiden, so erhaltene produkte und diese enthaltende pharmazeutische zusammensetzungen
ATE92056T1 (de) Verfahren zur herstellung von 5-chlor-3chlorsulfonyl-2-thiophencarbonsaeureestern.
ATE85893T1 (de) Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis.
DE3884261D1 (de) Verfahren zur Herstellung von Fremdproteinen in Streptomyceten.
ATE122563T1 (de) Verwendung von 15-keto-prostansäure-derivaten zur herstellung eines medikaments für die verbesserung der ausscheidung des kaliumions.
ATE81495T1 (de) Verfahren zur herstellung von natriumfluoralkoholaten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time